We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies

Nvx2.5

Navitoclax Research

Mostly mechanism / observational

9 peer-reviewed studies

What the evidence says

Mostly mechanism / observational

Most Navitoclax studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.

Most evidence is from medium-quality meta-analyses and randomised trials published 2014–2026 with a typical study size of 125 participants.

Based on 9 studies · 1 meta-analysis · 2 RCTs · 125 total participants

Confidence

Moderate confidence

By outcome

Senescence & agingClears senescent cells and reduced neurodegeneration in animals; no human longevity data and serious thrombocytopenia risk (it is an oncology drug). · Not established (no human longevity data)
Mostly mechanism / observational5 studies
Safety profile
Mostly mechanism / observational3 studies

Steady research

2 studies in the last 5 years · Latest meta-analysis: 2014

201420202026

1Meta-Analysis2014

Kaefer A, Yang J, Noertersheuser P, Mensing S, Humerickhouse R, Awni W · Cancer Chemother Pharmacol (2014)

View source

2RCT2014

Xiong H, Pradhan RS, Nada A, Krivoshik AP, Holen KD, Rhodes JW · Anticancer Res (2014)

3RCT2015

Kipps TJ, Eradat H, Grosicki S, Catalano J, Cosolo W, Dyagil IS · Leuk Lymphoma (2015)

View source

4n=125 · medium study2025

Pemmaraju N, Somervaille TCP, Palandri F, Harrison C, Komrokji RS, Perkins A, Ayala Diaz RM, Lavie D, Tomita A, Feng Y, Qin Q, Harb J, Polepally AR, Potluri J, Garcia JS. · Blood neoplasia (2025)

The primary end point was spleen volume reduction of ≥35% (SVR 35 ) at week 24.
Secondary end points included ≥50% total symptoms score (TSS 50 ) reduction at week 24, bone marrow fibrosis (BMF) grade changes, anemia response, and safety.
With median follow-up of 21 months, SVR 35 rate was 23% at week 24 and 39% at any time on study (median duration: 11 months).

View source

5Review2026

In plain English: The ongoing shift from broad inhibition to precision reprogramming represents a promising but preliminary step in the treatment of age-related diseases.

Zhang W, Song S, Zhang Y, Pan Y, Hu D, Wang Y. · npj aging (2026)

Localized activity may reduce systemic toxicity and mitigate dose-limiting effects observed with traditional inhibitors. (3) Microbiome-epigenetic interplay: This strategy modulates the gut-liver axis to enhance senolytic efficacy.
Short-chain fatty acids (SCFAs), such as butyrate, epigenetically regulate drug transporter expression and suppress the SASP, while dietary interventions may create a microenvironment favorable to senolysis.
These approaches offer potentially more targeted and personalized therapeutic options but face significant challenges, including immunopathology, manufacturing complexity, off-target effects, and long-term safety concerns.

View source

6Preclinical2016

In plain English: Navitoclax was identified as a senolytic agent targeting the Bcl-2 family of anti-apoptotic proteins.

Zhu, Tchkonia, Fuhrmann-Stroissnigg, Dai, Ling, Stout · Aging cell (2016)

Identified navitoclax as a senolytic via Bcl-2-family inhibition
Established the mechanism senescent cells depend on for survival
A founding senolytic-screen result alongside dasatinib/quercetin work

View source

7Animal2018

In plain English: Clearance of senescent glial cells prevented tau-dependent pathology and cognitive decline in mice.

Bussian, Aziz, Meyer, Swenson, van Deursen, Baker · Nature (2018)

Senescent glial cells drive tau pathology; clearing them (navitoclax-class senolysis) was protective
Reduced neurodegeneration and preserved cognition in a tau mouse model
Extends the senolytic rationale to neurodegeneration

View source

8Animal2016

In plain English: Clearance of senescent cells by ABT263 rejuvenated aged and irradiated hematopoietic stem cells in mice.

Chang, Wang, Shao, Laberge, Demaria, Campisi · Nature medicine (2016)

Navitoclax (ABT263) cleared senescent cells in aged and total-body-irradiated mice
Rejuvenated hematopoietic and muscle stem-cell function
Influential proof that pharmacologic senolysis can restore stem-cell fitness

View source

9Review2020

In plain English: Senolytic drugs including navitoclax are reviewed from discovery toward clinical translation.

Kirkland, Tchkonia · Journal of internal medicine (2020)

Review of senolytics including navitoclax, D+Q, and fisetin
Covers the Bcl-2-inhibitor class and its platelet-toxicity limitation
Frames the translational gap and next-gen designs

View source Free full text

View in Research Library

Navitoclax Research

Mostly mechanism / observational

Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of navitoclax (ABT-263) induced thrombocytopenia.

Studying navitoclax, a targeted anticancer drug, in healthy volunteers--ethical considerations and risk/benefit assessments and management.

A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia.

Addition of navitoclax to ruxolitinib for patients with myelofibrosis with progression or suboptimal response

Emerging strategies in senotherapeutics: from broad-spectrum senolysis to precision reprogramming

Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors.

Clearance of senescent glial cells prevents tau-dependent pathology and cognitive decline.

Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice.

Senolytic drugs: from discovery to translation.